Congress Appropriates $2.8 Million to Complete Department of Defense Research on ECASOL.

Business Editors

LAS VEGAS--(BUSINESS WIRE)--Nov. 20, 2002

Electro-Chemical Technologies Ltd. (Pink Sheets: ELCH) announced today that the United States Congress has appropriated $2.8 million for the Department of Defense (DoD) to complete military testing on ELCH's patented decontamination technology, known as ECASOL. The appropriation is contained in the 2003 Defense Appropriation Bill and the National Defense Authorization Act. The act was signed into law by the President yesterday.

At the conclusion of the test program, ELCH expects to make its ECASOL decontamination technology commercially available to the military and to civilian consequence management teams (police, fire departments and paramedics). ECASOL can be produced on the site of any biological decontamination, on demand. A deployed ECASOL generator requires only salt, water, and power to produce the decontaminant. ELCH believes the commercial availability of ECASOL will make an important contribution to the Homeland Defense effort by substantially increasing the number of persons that can be decontaminated in short timeframes in the event of exposure to a weapons of mass destruction (chemical or biological) attack.

For the last three years, the DoD's research program has been testing ECASOL's effectiveness as a decontaminant against biological and chemical weapons of mass destruction. Test results have already confirmed that ECASOL is a highly effective decontaminant which kills biological agents such as the anthrax spore on contact, without harming the environment. The results have led experts to conclude that ECASOL is a "breakthrough" technology in comparison with high test hypochlorite (HTH). HTH, the most widely used military decontaminant, requires 30 minutes to kill the anthrax spore and is a toxic chemical that requires special handling and must be treated as hazardous waste. The final phase of the research program will optimize ECASOL for use against broad spectrum biological agents, including the anthrax spore.

Electro-Chemical Technologies Ltd., a Nevada-based company trading in the Pink Sheets under the symbol ELCH, is engaged in the business of developing and commercializing its patented Electro-Chemical Activation (ECA) technology primarily in the areas of military and civil consequence management of biological and chemical decontamination programs, food safety, medical/healthcare and residential and industrial water treatment.

Safe Harbor Statement: The statements in this press release regarding the line item appropriation, ECASOL testing results, potential benefits derived from the appropriation, the uses for ECASOL, side effects of HTH, potential results or benefits of the final ECA test program, future ECA applications, future opportunities and any other effect or benefits of ECASOL, application or availability of the company's products to the DoD or civilian consequence management teams, and any other statements, which are not historical facts, are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, costs and difficulties related to the testing and production, costs, delays, and any other difficulties related to the appropriation, actual benefits derived from ECASOL, risks and effects of legal and administrative proceedings and governmental regulation, future financial and operational results, competition, general economic conditions, and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. The company undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.